Royalty Report: Drugs, Pain, Delivery – Collection: 26028

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Pain
  • Delivery
  • Pharmaceuticals
  • Nanoparticles
  • Biotechnology
  • Personal Care Products
  • Therapeutic
  • Technical Know How

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26028

License Grant
The Israeli Licensor, the technology transfer company of the University, grants the Licensee an exclusive License in the Field with right to grant sublicenses to develop and commercialize the Licensed Technology  in the Territory.
License Property
The Licensor owns certain patents, rights, know-how and technical data regarding topical delivery of Amiket, a combination of amytriptine and ketamine for the treatment of pain, only by means of biodegradable nanoparticles.

The pain compound AmiKetâ„¢, a topical cream consisting of a patented combination of amitriptyline and ketamine that is in late stage development for the treatment of peripheral neuropathies and has received Orphan Drug Designation for Post Herpetic Neuralgia.

The patent application currently entitled NANOPARTICLES FOR DERMAL AND SYSTEMIC DELIVERY OF DRUGS
US

22/01/2010

61/297,314

US

24/01/2011

61/435,674

Field of Use
Field involves nanoparticles for topical delivery of active agents for the treatment of pain. Topical delivery of Amiket, a combination of amytriptine and ketamine for the treatment of pain, only by means of biodegradable nanoparticles (the 'Field').

The Licensee will develop and market the Technology and sponsor research in connection with the further development of the Technology.

IPSCIO Record ID: 28144

License Grant
The Licensee entered into a binding memorandum of understanding the Israeli Licensor, the technology transfer company of the University, regarding certain patents in connection with nanoparticles for topical delivery of the Licensee's neuropathic pain drug candidate ready for a Phase III clinical trial. The parties will be entered into a definitive license agreement within six months of the date of the MOU for the commercial development and marketing of the Technology worldwide.
License Property
The Licensor's patents in connection with nanoparticles for topical delivery for the Licensee's neuropathic pain drug candidate.
Field of Use
The pain compound AmiKetâ„¢, a topical cream consisting of a patented combination of amitriptyline and ketamine that is in late stage development for the treatment of peripheral neuropathies and has received Orphan Drug Designation for Post Herpetic Neuralgia.

IPSCIO Record ID: 3523

License Grant
On April 3, 2014, the parties entered into a Waiver and Amendment to the License Agreement, dated June 29, 2007, by and between us and Dalhousie, effective February 4, 2014.  Pursuant to the Amendment, the University has agreed to irrevocably waive the Licensee's obligation to pay a maintenance fee that was due on August 27, 2012 and August 27, 2013 and in any subsequent year. In addition, the parties have agreed to royalties. The parties also agreed to amend the timing and increase the amounts of the milestone payments payable under the Agreement.  In the original 2007 agreement, the Licensee was granted an exclusive license to certain patents for the topical use of tricyclic anti-depressants and NMDA antagonists as topical analgesics for neuralgia. The license covers worldwide rights to make, use, develop, sell and market products utilizing the licensed technology in connection with passive dermal applications.
License Property
These and other patents cover the combination treatment consisting of amitriptyline and ketamine in AmiKet. This technology has been incorporated into AmiKet.  It is indicated for post herpetic neuralgia, diabetic peripheral neuropathies, chemotherapy induced peripheral neuropathy, and erythromelalgia.
Field of Use
AmiKet has completed phase 1 and 2 clinical trials involving 1,600 subjects for the treatment of neuropathic pain.

Neuropathic pain is pain caused by damage or disease affecting the somatosensory nervous system. Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli (allodynia).

IPSCIO Record ID: 28295

License Grant
The Israeli Licensor, the technology transfer company of the University, grants the Licensee the exclusive License in the Field, with right to grant sublicenses, to develop and commercialize the Licensed Technology in the Territory, for drug delivery.
License Property
The Licensor owns certain patent/s, rights, know-how and technical data

The Licensed Technology shall consist of the Licensed Patents, the Know-How and the Research Results in patent application currently entitled Nanoparticles For Dermal and Systemic Delivery of Drugs.

Field of Use
The Licensee will develop application for the Topical delivery of  Cyclosporin A, only by means of biodegradable nanoparticles.

IPSCIO Record ID: 48798

License Grant
The agreement, between two Israeli parties, is an exclusive sublicense, with a right to further sublicense as provided for herein below, to make commercial use of the License Technology, in order to develop, manufacture, market, distribute or sell a Product.
License Property
The patents shall mean the patent application currently entitled Nanoparticles for Dermal and Systemic Delivery of Drugs.
Field of Use
The use shall mean topical delivery of Cyclosporine A, only by means of biodegradable nanoparticles, for all drug indications applied on the skin and the skull. For the avoidance of doubt, the Field does not involve any mechanism for delivery except topical of Cyclosporine A.

IPSCIO Record ID: 83691

License Grant
Licensor grants an exclusive option to negotiate an exclusive worldwide royalty-bearing license, including the right to grant sublicenses, to make, use, sell, offer for sale and import products under all Licensor’s right, title and interest in Product.
License Property
The product is AmiKetâ„¢ and Amiketâ„¢ Nano, which are proprietary combinations of amitriptyline and ketamine in topical formulations to treat neuropathic pain, and related product formulations, technical information, clinical data, know-how, patents and patent applications, and trademarks.
Field of Use
The field of use pertains to the drug industry and the topical treatment of neuropathic pain.

IPSCIO Record ID: 390379

License Grant
Licensor of Europe granted the Licensee an exclusive, sublicensable, perpetual, worldwide (excluding certain jurisdictions identified in the License Agreement) and irrevocable right and license to certain of Licensor’s licensed patents, know-how, and technological information, including access to Licensor’s research, development and manufacturing capabilities, to enable the further development, manufacture, promotion and commercialization of Wafermine™ and certain other existing and to be developed Licensor wafer-based delivery technologies, in all cases for sublingual administration of ketamine. In addition, Licensor will supply the Company with sufficient product for the potential treatment of 400 patients, with further supplied amounts to be determined by the parties. The Company granted Licensor an exclusive license to exploit technology developed under the License Agreement outside of the licensed territory and to undertake limited, non-exclusive research and development activities in the territory.
License Property
Wafermine™ is a wafer-based delivery technology now known as SLS-003. It is delivered using a proprietary fast-dissolving wafer-based drug delivery platform technology known as WaferiX™, the world’s first patented sublingual racemic ketamine wafer. Ketamine is an N -methyl-D-aspartate antagonist.
Field of Use
The rights grants are for sublingual administration of ketamine for the treatment of pain.

IPSCIO Record ID: 369241

License Grant
Licensor grants to the Licensee of Ireland
– the exclusive right and license to make, have made, use, offer for sale, sell and import the Product in the Territory, including the right to record sales for its own account;
– in each case, solely for use in the Field and Territory and in connection with Licensees development and Commercialization of the Product and to otherwise exercise Licensees rights and perform its obligations under this Agreement
Know-How;
— an exclusive license under the Product Patents Rights and Product
— an exclusive license under the SAIB Patent Rights;
— an exclusive license under the Re-appliable Patent Rights; and
— an exclusive sublicense under Licensors license to the Epicept Intellectual Property; and,
– an exclusive license and right of cross-reference to all Development Data Controlled by Licensor in existence as of the Effective Date solely to exercise its rights and licenses under this Agreement with respect to the Product.

Licensor grants an exclusive license to use the Licensor Trademark in the Territory solely in connection with the Commercialization of Product in the Territory.

License Property
Licensor is the owner of a proprietary product for pain treatment consisting of a bupivacaine transdermal patch as described below and certain patents and know-how relating thereto.

Product means the product under development by Licensor currently known as ELADURâ„¢.

Bupivacaine means 1-butyl-N-(2,6-dimethylphenyl) piperidine-2-carboxamide, including any and all pharmaceutically acceptable salts, solvates, prodrugs, esters, free base forms, enantiomers (and racemic or other mixtures of said enantiomers) thereof.

Topical Bupivacaine Product means any formulation containing Bupivacaine, either alone or in combination with one or more other active ingredients. for use in the Field.

Licensor Trademark means the trademark rights to the mark ELADURâ„¢ and similar rights under the laws of any Governmental Entity, including all goodwill associated therewith, and all applications, registrations, extensions and renewals relating thereto.

Patents rights include Transdermal Delivery System, and, Methods for Transdermal Drug Administration.

Field of Use
ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.

Bupivacaine is a prescription medication used as a local anesthetic (numbing medicine). Bupivacaine blocks the nerve impulses that send pain signals to your brain.  Bupivacaine injection is used to numb an area of your body during or after surgery or other procedures, childbirth, or dental work.

The Field means all pharmaceutical applications, including the treatment of pain, for human health.

IPSCIO Record ID: 310525

License Grant
Licensor grants a sole and exclusive license, including the right to sublicense, to all of the Intellectual Property Rights including the rights to develop,  use, market, promote, and sell the Product in the Territory.

For the Option for additional Territories of Canada and Mexico, Licensor grants an option to extend this Agreement to cover a sole and exclusive, license, on royalty terms that are substantially similar to those set forth in this Agreement, with the right to sublicense, to the Intellectual Property Rights including the right to develop, use, market, promote, and sell Product in Canada and Mexico.

For the Trademark License Grant, Licensor grants an exclusive right and license, to use the Trademark in connection with the marketing, promotion, advertising, and sale or other distribution of the Product in the Territory.

For the Submission Package, Licensor grants an option for a sole and exclusive license, with the right to sublicense, to the Intellectual Property Rights including the right to develop, use, market, promote, and sell a topical formulation of lidocaine in a gel formulation (Development Product), whether sold over-the-counter or by prescription, for human use which falls within the claims of the Licensed Patents.

If Licensee exercises its option, the parties agree to license such Intellectual Property Rights on terms to be mutually agreed to by the parties.based substantially on the terms of this Agreement.

License Property
Licensor is the owner of certain patents, know-how and trademarks for the topical treatment of post-herpetic neuralgia, other forms of neuralgia and neuropathy and has the right to grant licenses to said patents, know-how, and trademarks.

The Patents are titled Method for Treating Nerve Injury Pain Associated with Shingles;  Method for Treating Nerve Injury Pain Associated with Shingles Herpes-Zoster and Post-Herpetic Neuralgia) by Topical Application Of Lidocaine;  Method for Treating Pain Associated with Herpes Zoster and Post-Herpetic Neuralgia;  and,  Method for Treating Nerve Injury Pain Associated with Shingles (Herpes-zoster and Post Herpetic Neuralgia) by Topical Application of Lidocaine.

Product means any topical formulation of lidocaine in a bandage and/or transdermal (Patch) formulation, whether sold over-the counter or by prescription, for human use which falls within the claims of the Licensed Patents.

Trademark shall mean the trademarks LIDODERM or TAKON that may be used to market the Product in the Territory.

Lidocaine patches are used to relieve the pain of post-herpetic neuralgia (PHN; the burning, stabbing pains, or aches that may last for months or years after a shingles infection). Lidocaine is in a class of medications called local anesthetics. It works by stopping nerves from sending pain signals.

Field of Use
This agreement is for the topical treatment of post-herpetic neuralgia, other forms of neuralgia and neuropathy in the United States.

Lidoderm(R) (Lidocaine Patch 5%) is a transdermal pharmaceutical patch product for the treatment of post-herpetic neuralgia.

Postherpetic neuralgia is the most common complication of shingles. The condition affects nerve fibers and skin, causing burning pain that lasts long after the rash and blisters of shingles disappear. The chickenpox (herpes zoster) virus causes shingles.

Licensee is a pharmaceutical company engaged in research, development, and marketing of various products, including pain management products.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.